Bayer Applauds Rivaroxaban
Bayer recently announced the top line results, and claimed that Rivaroxaban (Xarelto) plus standard therapy was observed to reduce the death rates, stroke as well as myocardial infarction, during a study of acute coronary syndrome. However, the company has claimed that the oral direct factor ‘Xa inhibitor’ has some properties that tend to increase risk of bleeding.
Renowned company, Johnson & Johnson, also works in collaboration with the company to market the Rivaroxaban, across the United States. In addition the FDA has approved the drug to avoid the incidents of deep vein thrombosis among patients receiving joint surgery.
Sources have confirmed that the FDA is evaluating its application to market the medication to obstruct the incidents of stroke, particularly among patients with non-valvular atrial fibrillation.
“As expectations for Xarelto in acute coronary syndrome were zero, this is a positive for Bayer”, explained a Bernstein Research.
While briefing about a latest blood-thinner, Xarelto, the Chief Executive Officer of Bayer, has notified that the drug was developed in collaboration with Johnson & Johnson.
Xarelto is believed to reduce the rates of heart attack, stroke as well as deaths due to cardiovascular diseases among patients living with acute coronary syndrome.
The plunge of one man may be the turning point...Read More
The triumphant return to their home stadium by...Read More
French Defense Minister Florence Parly says...Read More
The countries of...Read More
In terms of mining investment desirability, South...Read More
The Societe Generale in France anticipates that...Read More